Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561956 | 1.00 | EPHX2 (0.63) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL29401210 | 1.00 | EPHX2 (0.63) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL7913189 | 0.96 | EPHX2 (0.59) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL8366872 | 0.90 | EPHX2 (0.75) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL5189498 | 0.88 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL22932201 | 0.88 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL15939984 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL30833078 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL29341843 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL8239124 | 0.87 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4836455-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-2281580-A2 | Labeled gastrin releasing peptides (GRP) | Bracco Imaging S.p.A (IT) | 2011-02-09 | — | — | EP | claimed |
| EP-1585549-A4 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING SPA (IT) | 2009-07-29 | — | — | EP | claimed |
| US-7226577-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING, S. P. A. (IT) | 2007-06-05 | — | — | US | claimed |
| US-20060239923-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-10-26 | — | — | US | claimed |
| EP-1585549-A2 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | Bracco Imaging S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | claimed |
| WO-2004065407-A2 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2004-08-05 | — | — | WO | claimed |
| US-20040136906-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2004-07-15 | — | — | US | claimed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| CN-119431260-A | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2025-02-14 | — | — | CN | disclosed |
| CN-114401947-B | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2024-11-29 | — | — | CN | disclosed |
| CN-115326937-B | Solid-phase probe for capturing genotoxic impurities and use method and application thereof | 山东省食品药品检验研究院 | 2024-06-18 | — | — | CN | disclosed |
| US-11639373-B2 | Therapeutic and diagnostic agents for cancer | Technische Universität München (DE) | 2023-05-02 | — | — | US | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6326403-B1 | CARDIOVASCULAR DISORDERS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2001-12-04 | — | — | US | disclosed |
| CN-1309633-A | Diacylhydrazine derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2001-08-22 | — | — | CN | disclosed |
| EP-0876395-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997022618-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | GRPR, MLNR, NPBWR1 | EPHX2 3747/4885KMT2A 4045/4885FABP7 1118/4885 |
| US-20060239923-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | EPHX2 2802/4885KMT2A 4189/4885FABP7 867/4885 |
| US-20040136906-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, MLNR | EPHX2 3641/4885KMT2A 4142/4885FABP7 1103/4885 |
| US-11639373-B2 | Therapeutic and diagnostic agents for cancer | CXCR4, CXCL12, CXCR3 | EPHX2 1297/4885KMT2A 4704/4885FABP7 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.